Asset Details
Do you wish to reserve the book?
Tirabrutinib: First Approval
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Tirabrutinib: First Approval
Do you wish to request the book?
Tirabrutinib: First Approval
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Tirabrutinib: First Approval
2020
Overview
Tirabrutinib (Velexbru
®
) is an orally administered, small molecule, Bruton's tyrosine kinase (BTK) inhibitor being developed by Ono Pharmaceutical and its licensee Gilead Sciences for the treatment of autoimmune disorders and haematological malignancies. Tirabrutinib irreversibly and covalently binds to BTK in B cells and inhibits aberrant B cell receptor signalling in B cell-related cancers and autoimmune diseases. In March 2020, oral tirabrutinib was approved in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma. Tirabrutinib is also under regulatory review in Japan for the treatment of Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma. Clinical development is underway in the USA, Europe and Japan for autoimmune disorders, chronic lymphocytic leukaemia, B cell lymphoma, Sjogren's syndrome, pemphigus and rheumatoid arthritis. This article summarizes the milestones in the development of tirabrutinib leading to the first approval of tirabrutinib for the treatment of recurrent or refractory primary central nervous system lymphoma in Japan.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors
/ Agammaglobulinaemia Tyrosine Kinase - metabolism
/ Autoimmune Diseases - drug therapy
/ Autoimmune Diseases - metabolism
/ Central Nervous System Neoplasms - drug therapy
/ Central Nervous System Neoplasms - metabolism
/ Chronic lymphocytic leukemia
/ Humans
/ Imidazoles - administration & dosage
/ Immunosuppressive Agents - administration & dosage
/ Immunosuppressive Agents - chemistry
/ Immunosuppressive Agents - pharmacology
/ Kinases
/ Leukemia
/ Lymphoma
/ Medicine
/ Plasma
/ Protein Kinase Inhibitors - administration & dosage
/ Protein Kinase Inhibitors - chemistry
/ Protein Kinase Inhibitors - pharmacology
/ Pyrimidines - administration & dosage
/ Tyrosine
